Akyildiz Z I, Polat S, Yurekli B S, Kocabas G U, Tuluce K, Tuluce S Y, Kocabas U, Bozkaya G, Yuksel A, Nazli C
Department of Cardiology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Basin Sitesi, 35360, Izmir, Turkey.
Department of Internal Medicine, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey.
J Endocrinol Invest. 2015 Mar;38(3):361-6. doi: 10.1007/s40618-014-0185-3. Epub 2014 Oct 14.
The hormone fibroblast growth factor 21 (FGF-21) regulates carbohydrate and lipid homeostasis. FGF-21 represents an attractive novel therapy for obesity since administration of FGF-21 has been shown to improve metabolic abnormalities in obese animal models. We investigated FGF-21 and its relationship with epicardial fat thickness (EFT), metabolic parameters, and inflammatory markers in premenopausal obese women compared to controls with similar Systematic Coronary Risk Evaluation (SCORE) project risk profiles.
Forty-five obese premenopausal women with body mass index (BMI) ≥30 kg/m(2) and 41 control premenopausal women with BMI <25 kg/m(2) with similar SCORE project risk profiles were included in this case-control study. EFT was evaluated by two-dimensional transthoracic echocardiography. Serum FGF-21 was measured with an ELISA kit.
FGF-21 and EFT were significantly higher in obese women compared to controls (p < 0.001). Multiple stepwise linear regression analysis showed that EFT, BMI, and triglycerides (TG) independently contributed to FGF-21 (R(2) = 0.757, p < 0.001). However, homeostasis model assessment of insulin resistance (HOMA-IR), visceral ectopic fat, and inflammatory markers were not found as a direct contributor to serum FGF-21 level (p > 0.05).
EFT, BMI, and TG may play an important role in predicting serum FGF-21 level which may be a potential therapeutic target in cardiometabolic disorders in the future.
成纤维细胞生长因子21（FGF - 21）可调节碳水化合物和脂质稳态。FGF - 21是一种有吸引力的新型肥胖治疗方法，因为在肥胖动物模型中已证明给予FGF - 21可改善代谢异常。我们研究了绝经前肥胖女性中FGF - 21及其与心外膜脂肪厚度（EFT）、代谢参数和炎症标志物的关系，并与具有相似系统性冠状动脉风险评估（SCORE）项目风险概况的对照组进行比较。
本病例对照研究纳入了45名体重指数（BMI）≥30 kg/m²的绝经前肥胖女性和41名BMI <25 kg/m²且具有相似SCORE项目风险概况的绝经前对照女性。通过二维经胸超声心动图评估EFT。用ELISA试剂盒测定血清FGF - 21。
与对照组相比，肥胖女性的FGF - 21和EFT显著更高（p < 0.001）。多元逐步线性回归分析表明，EFT、BMI和甘油三酯（TG）独立影响FGF - 21（R² = 0.757，p < 0.001）。然而，未发现胰岛素抵抗稳态模型评估（HOMA - IR）、内脏异位脂肪和炎症标志物是血清FGF - 21水平的直接影响因素（p > 0.05）。
EFT、BMI和TG可能在预测血清FGF - 21水平中起重要作用，血清FGF - 21水平未来可能是心脏代谢紊乱的潜在治疗靶点。
